OSHA recently revealed its top 10 most frequently cited standards in the 2024 fiscal year using preliminary data. This information is valuable for businesses of all kinds, as it helps them identify common exposures that affect their workforce and gives them the information they need to plan their compliance programs.
For 2024, the top 10 most cited standards were as follows:
- Fall protection—General requirements: 6,307 violations
- Hazard communication: 2,888 violations
- Ladders: 2,573 violations
- Respiratory Protection: 2,470 violations
- Lockout/tagout: 2,443 violations
- Powered industrial trucks: 2,248 violations
- Fall protection—Training requirements: 2,050
- Scaffolding: 1,873 violations
- Personal protective and life-saving equipment—Eye and face protection: 1,814 violations
- Machine guarding: 1,541 violations
Several standards changed positions from fiscal year 2023. For instance, “respiratory protection” moved up to number four and“scaffolding” moved down from number four to number eight. What’s more, “fall protection—general requirements” remained OSHA’s most frequently cited standard for the 14th consecutive fiscal year.
Keep in mind that this data is preliminary and may be subject to change.
For additional risk management resources, contact INSURICA today.
This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice. ©2024 Zywave, Inc. All rights reserved
About the Author
Share This Story
Related Blogs
Protecting Athletic Fields and Outdoor Facilities Over the Summer
Summer is a key season for school athletic fields [...]
RxDC Reporting: What Employers Should Do Before the June 1 Deadline
Each year, group health plans must report detailed prescription drug and healthcare spending data to the Centers for Medicare & Medicaid Services (CMS). This reporting—commonly referred to as RxDC reporting—is due by June 1 and applies to most employer-sponsored group health plans that offer prescription drug coverage.
Chronic Condition Management 2.0: GLP-1 Alternatives and New Digital Therapeutics
Chronic conditions have long been the primary driver of employer healthcare spending, but 2026 marks a turning point in how organizations are approaching prevention, treatment, and long-term management. With GLP-1 medications dominating headlines — and budgets — employers are urgently exploring complementary or alternative strategies that can improve outcomes without unsustainable cost growth. The result is a new wave of digital therapeutics, metabolic health programs, and integrated care models that promise a more balanced approach to chronic disease management.